metoprolol has been researched along with Kidney Failure, Chronic in 25 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." | 9.09 | Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001) |
| "Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear." | 7.83 | Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. ( Chen, TH; Hong, CY; Sue, YM; Tang, CH; Wang, CC, 2016) |
| "The African American Study of Kidney Disease and Hypertension examined the effect on renal function decline of 2 blood pressure (BP) goals (low mean arterial pressure [MAP] < or =92 versus usual MAP 102 to 107 mm Hg) and 3 antihypertensives (ramipril versus amlodipine versus metoprolol)." | 5.11 | Blood pressure control, drug therapy, and kidney disease. ( Agodoa, LY; Cheek, D; Contreras, G; Dowie, D; Greene, T; Junco, G; Lash, J; Lipkowitz, M; Miller, ER; Ojo, A; Sika, M; Toto, RD; Wilkening, B, 2005) |
| "Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." | 5.09 | Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001) |
| "26 patients with hypertension while on hemodialysis or continuous ambulatory peritoneal dialysis for end-stage renal diseases were treated first with enalapril and then changed to metoprolol." | 5.08 | A comparison of the effect of enalapril and metoprolol on renal function, potassium balance, lipid profile, cardiac function, exercise tolerance and quality of life in hypertensive dialysis patients. ( Lai, KN; Lam, WK; Li, KT; Lui, SF; Nicholls, MG; Wong, KC; Woo, KS, 1995) |
| "In a double-blind, randomized trial with 26 male white patients with essential hypertension in World Health Organization Stages I and II, we examined the impact of calcium entry blockade (5 to 10 mg/day isradipine, N = 14) and beta-blockade (100 to 200 mg/day metoprolol, N = 12) on early markers of hypertensive nephropathy before and after 7 weeks' treatment." | 5.07 | Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy. ( Rockstroh, J; Rüddel, H; Schächinger, H; Schlebusch, H; Schmieder, RE; Schulte, W, 1992) |
| "Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear." | 3.83 | Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. ( Chen, TH; Hong, CY; Sue, YM; Tang, CH; Wang, CC, 2016) |
| " Two days before hospitalization, he developed cough and sputum and he visited an outpatient clinic, where dextromethorphan was prescribed." | 3.77 | Myoclonus after dextromethorphan administration in peritoneal dialysis. ( Fujita, Y; Ito, Y; Maeda, K; Nagamatsu, T; Nagura, F; Nomura, A; Shimizu, H; Tanaka, A; Tomino, T; Watanabe, T; Yamaguchi, M, 2011) |
| "The magnitude of proteinuria is associated with a graded increase in the risk of progression to end-stage renal disease and cardiovascular events." | 2.71 | The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. ( Bakris, GL; Greene, T; Hebert, L; Lea, J; Lipkowitz, M; Massry, S; Middleton, J; Miller, E; Rostand, SG; Smith, W, 2005) |
| "The influence of chronic renal failure on the stereoselective metabolism of rac-metoprolol was investigated in 15 hypertensive patients, 7 of them with chronic renal failure and 8 with normal renal function." | 2.71 | Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients. ( Cerqueira, PM; Coelho, EB; Geleilete, TJ; Goldman, GH; Lanchote, VL, 2005) |
| "Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD." | 2.70 | Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. ( Agodoa, LY; Appel, LJ; Bakris, G; Charleston, J; Cheek, D; Douglas-Baltimore, JG; Gassman, J; Glassock, R; Greene, T; Hebert, L; Jamerson, K; Lewis, J; Middleton, JP; Phillips, RA; Rostand, SG; Toto, RD; Wright, JT, 2002) |
| "Hypertension is the second leading attributable cause of end-stage renal disease in the United States today." | 2.43 | Lessons from the African-American Study of Kidney Disease and Hypertension: an update. ( Toto, RD, 2006) |
| " In conclusion, this study suggests that the increase of the bioavailability of propranolol in ESRD is partly induced by the inhibition of the hepatic metabolism of CYP1A2 by xanthine in the uremic serum." | 1.40 | Possibility of decrease in CYP1A2 function in patients with end-stage renal disease. ( Furukubo, T; Izumi, S; Minegaki, T; Nagatomo, M; Nishiguchi, K; Sugimoto, S; Tsujimoto, M; Yamakawa, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (24.00) | 18.7374 |
| 1990's | 5 (20.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 3 (12.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, H | 1 |
| Sim, JJ | 1 |
| Shi, J | 1 |
| Shaw, SF | 1 |
| Lee, MS | 1 |
| Neyer, JR | 1 |
| Kovesdy, CP | 1 |
| Kalantar-Zadeh, K | 1 |
| Jacobsen, SJ | 1 |
| Tsujimoto, M | 1 |
| Sugimoto, S | 1 |
| Nagatomo, M | 1 |
| Furukubo, T | 1 |
| Izumi, S | 1 |
| Yamakawa, T | 1 |
| Minegaki, T | 1 |
| Nishiguchi, K | 1 |
| Tang, CH | 1 |
| Wang, CC | 1 |
| Chen, TH | 1 |
| Hong, CY | 1 |
| Sue, YM | 1 |
| Tanaka, A | 1 |
| Nagamatsu, T | 1 |
| Yamaguchi, M | 1 |
| Nomura, A | 1 |
| Nagura, F | 1 |
| Maeda, K | 1 |
| Tomino, T | 1 |
| Watanabe, T | 1 |
| Shimizu, H | 1 |
| Fujita, Y | 1 |
| Ito, Y | 1 |
| Wright, JT | 2 |
| Bakris, G | 1 |
| Greene, T | 4 |
| Agodoa, LY | 3 |
| Appel, LJ | 1 |
| Charleston, J | 2 |
| Cheek, D | 3 |
| Douglas-Baltimore, JG | 1 |
| Gassman, J | 2 |
| Glassock, R | 1 |
| Hebert, L | 3 |
| Jamerson, K | 2 |
| Lewis, J | 1 |
| Phillips, RA | 2 |
| Toto, RD | 4 |
| Middleton, JP | 1 |
| Rostand, SG | 2 |
| Lea, J | 2 |
| Lipkowitz, M | 3 |
| Massry, S | 2 |
| Middleton, J | 2 |
| Miller, E | 1 |
| Smith, W | 2 |
| Bakris, GL | 2 |
| Contreras, G | 1 |
| Junco, G | 1 |
| Dowie, D | 2 |
| Lash, J | 2 |
| Miller, ER | 2 |
| Ojo, A | 2 |
| Sika, M | 1 |
| Wilkening, B | 1 |
| Cerqueira, PM | 1 |
| Coelho, EB | 1 |
| Geleilete, TJ | 1 |
| Goldman, GH | 1 |
| Lanchote, VL | 1 |
| Amann, K | 1 |
| Hofstetter, J | 1 |
| Câmpean, V | 1 |
| Koch, A | 1 |
| Gross, ML | 1 |
| Veelken, R | 1 |
| Ritz, E | 1 |
| Dhaun, N | 1 |
| Ferro, CJ | 1 |
| Davenport, AP | 1 |
| Haynes, WG | 1 |
| Goddard, J | 1 |
| Webb, DJ | 1 |
| Yee, J | 1 |
| Zumkley, H | 1 |
| Wagner, H | 1 |
| Hoffmanns, H | 1 |
| Seetzen-Kanaan, G | 1 |
| Vetter, H | 1 |
| Zideck, W | 1 |
| Raidt, H | 1 |
| Kellinghaus, H | 1 |
| Parving, HH | 1 |
| Andersen, AR | 1 |
| Smidt, UM | 1 |
| Svendsen, PA | 1 |
| Wong, KC | 1 |
| Woo, KS | 1 |
| Lam, WK | 1 |
| Li, KT | 1 |
| Lai, KN | 1 |
| Nicholls, MG | 1 |
| Lui, SF | 1 |
| Gonsorcík, J | 1 |
| Szakács, M | 1 |
| Palko, S | 1 |
| Mydlík, M | 1 |
| Shiigai, T | 1 |
| Hattori, K | 1 |
| Iwamoto, H | 1 |
| Owada, A | 1 |
| Appel, L | 1 |
| Beck, G | 1 |
| Bourgoignie, J | 1 |
| Briggs, JP | 1 |
| Cleveland, W | 1 |
| Douglas, JG | 1 |
| Douglas, M | 1 |
| Faulkner, M | 1 |
| Gabriel, A | 1 |
| Hall, Y | 1 |
| Hiremath, L | 1 |
| Johnson, CJ | 1 |
| Kopple, J | 1 |
| Kusek, J | 1 |
| Lewis, JB | 1 |
| Norris, K | 1 |
| O'Connor, D | 1 |
| Pogue, V | 1 |
| Rahman, M | 1 |
| Randall, OS | 1 |
| Rostand, S | 1 |
| Schulman, G | 1 |
| Thornley-Brown, D | 1 |
| Tisher, CC | 1 |
| Xu, S | 1 |
| McConaghy, JR | 1 |
| de Fremont, JF | 1 |
| Coevoet, B | 1 |
| Andrejak, M | 1 |
| Makdassi, R | 1 |
| Quichaud, J | 1 |
| Lambrey, G | 1 |
| Gueris, J | 1 |
| Caillens, C | 1 |
| Harichaux, P | 1 |
| Alexandre, JM | 1 |
| Fournier, A | 1 |
| Schmieder, RE | 1 |
| Rüddel, H | 1 |
| Schlebusch, H | 1 |
| Rockstroh, J | 1 |
| Schächinger, H | 1 |
| Schulte, W | 1 |
| Nordlander, M | 1 |
| Havu, N | 1 |
| Castellino, P | 1 |
| Bia, M | 1 |
| DeFronzo, RA | 1 |
| Ashouri, OS | 1 |
| Takeda, K | 1 |
| Kusano, E | 1 |
| Asano, Y | 1 |
| Hosoda, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| African American Study of Kidney Disease and Hypertension[NCT04364139] | Phase 3 | 1,094 participants (Actual) | Interventional | 1995-02-01 | Completed | ||
| Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)[NCT03195023] | Phase 4 | 106 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.[NCT04662723] | Phase 4 | 878 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metoprolol and Kidney Failure, Chronic
| Article | Year |
|---|---|
Lessons from the African-American Study of Kidney Disease and Hypertension: an update.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2006 |
11 trials available for metoprolol and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blac | 2005 |
Blood pressure control, drug therapy, and kidney disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2005 |
Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Cytochrome P-450 CYP2D6; Debrisoquin; F | 2005 |
Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease.
Topics: Adult; Blood Pressure; Cross-Over Studies; Double-Blind Method; Doxazosin; Enalapril; Endothelin Rec | 2007 |
A comparison of the effect of enalapril and metoprolol on renal function, potassium balance, lipid profile, cardiac function, exercise tolerance and quality of life in hypertensive dialysis patients.
Topics: Adult; Anemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Cell Count; | 1995 |
Long-term enalapril therapy in patients with chronic renal failure on a low-protein diet. A prospective randomized comparison with metoprolol.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cholesterol, HDL; Creatinine; Diet, Protein-Re | 1998 |
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2001 |
What is the best treatment for slowing the progression to end-stage renal disease (ESRD) in African Americans with hypertensive nephropathy?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Double-Blind Method; Female; Glomeru | 2001 |
Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy.
Topics: Antihypertensive Agents; Dihydropyridines; Double-Blind Method; Humans; Hypertension; Isradipine; Ki | 1992 |
Metabolic response to exercise in dialysis patients.
Topics: Adult; Blood Glucose; Blood Pressure; Catecholamines; Fatty Acids, Nonesterified; Female; Glucose; H | 1987 |
13 other studies available for metoprolol and Kidney Failure, Chronic
| Article | Year |
|---|---|
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Dea | 2021 |
Possibility of decrease in CYP1A2 function in patients with end-stage renal disease.
Topics: Acetaminophen; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Humans; Kidney Failure, Chronic; Li | 2014 |
Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2016 |
Myoclonus after dextromethorphan administration in peritoneal dialysis.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Antitussive Agents; Cough; Cytochrome P-450 CY | 2011 |
Nonhypotensive dose of beta-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure.
Topics: Adrenergic beta-Antagonists; Animals; Arterioles; Blood Pressure; Capillaries; Coronary Vessels; End | 2006 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp | 2008 |
[Immediate effect of beta receptor blockaders on electrolyte metabolism].
Topics: Adrenergic beta-Antagonists; Electrolytes; Humans; Hypertension; Kidney Failure, Chronic; Metoprolol | 1982 |
Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus; Diabetic Nephropathies; Diuretics | 1983 |
[Pharmacotherapy of silent myocardial ischemia in patients on hemodialysis].
Topics: Adrenergic beta-Agonists; Adult; Aged; Calcium Channel Blockers; Female; Humans; Kidney Failure, Chr | 1996 |
Effects of antihypertensive drugs on dialysis-resistant hypertension, plasma renin and dopamine betahydroxylase activities, metabolic risk factors and calcium phosphate homeostasis: comparison of metoprolol, alphamethyldopa and clonidine in a cross-over t
Topics: Clonidine; Dopamine beta-Hydroxylase; Humans; Hypertension, Renal; Kidney Failure, Chronic; Methyldo | 1979 |
Effects of chronic felodipine treatment on renal function and morphology in SHR.
Topics: Animals; Blood Pressure; Creatinine; Drug Synergism; Felodipine; Female; Glomerulosclerosis, Focal S | 1992 |
Metoprolol-induced hyperkalemia in a diabetic with advanced renal failure.
Topics: Diabetic Nephropathies; Humans; Hyperkalemia; Kidney Failure, Chronic; Male; Metoprolol; Middle Aged | 1985 |
Beta-antagonist and secondary hyperparathyroidism in chronic renal failure.
Topics: Adult; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Metoprolol; Mi | 1985 |